logo-loader
viewRedx Pharma PLC

Redx Pharma receives approval to re-commence clinical trial of RXC004

Lisa Anson, chief executive of Redx Pharma Plc (LON:REDX), tells Proactive London's Andrew Scott they've received the regulatory green light to re-commence its phase I/II clinical trial of RXC004 on people with solid tumours.

It means the company is on track to restart the study as planned in the first-half.

RXC004 is a new breed of cancer drug called a porcupine inhibitor, with this particular formulation targeting the Wnt signalling pathway, which known to be heavily involved in cell growth and division.

Quick facts: Redx Pharma PLC

Price: 14.25 GBX

AIM:REDX
Market: AIM
Market Cap: £27.08 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Redx Pharma PLC named herein, including the promotion by the Company of Redx Pharma PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Morning Report: FTSE 100 rallies as Italians ban short selling

Headlines from the Proactive UK newsroom. The FTSE 100 rallied this morning even though Asian markets suffered more pain overnight.  London’s blue chip index opened around 157 points higher at 5,395 after giving up 639 points yesterday. Italy has introduced a temporary ban on...

2 weeks, 3 days ago

2 min read